GlassScriptPhysician profile
Steven A Campau
NPI 1255440954
$7,902.90
in general payments reported to CMS, 2019-2025
42 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,872 · 2022: $314 · 2023: $1,777 · 2024: $1,915 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,717.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,231.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,121.48 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $920.28 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $490.63 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $406.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $394.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $334.67 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $304.31 | 2019-2025 | Xarelto, Spravato |
| Mylan Specialty L.P. | $277.00 | 2022-2024 | Yupelri |
| Abbvie INC. | $213.04 | 2023-2025 | Vraylar, Viberzi, Linzess |
| Merck Sharp & Dohme LLC | $204.95 | 2019-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $166.02 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $162.23 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $156.23 | 2024 | Watchman Access System, Eluvia |
| Exact Sciences Corporation | $156.06 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Campau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.